These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30341686)

  • 1. The concept of the okadaic acid class of tumor promoters is revived in endogenous protein inhibitors of protein phosphatase 2A, SET and CIP2A, in human cancers.
    Fujiki H; Sueoka E; Watanabe T; Suganuma M
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2339-2349. PubMed ID: 30341686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer progression by the okadaic acid class of tumor promoters and endogenous protein inhibitors of PP2A, SET and CIP2A.
    Fujiki H; Sueoka E; Watanabe T; Komori A; Suganuma M
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9425-9433. PubMed ID: 37097392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1.
    Kauko O; Imanishi SY; Kulesskiy E; Yetukuri L; Laajala TD; Sharma M; Pavic K; Aakula A; Rupp C; Jumppanen M; Haapaniemi P; Ruan L; Yadav B; Suni V; Varila T; Corthals GL; Reimand J; Wennerberg K; Aittokallio T; Westermarck J
    J Biol Chem; 2020 Mar; 295(13):4194-4211. PubMed ID: 32071079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
    Farrell AS; Allen-Petersen B; Daniel CJ; Wang X; Wang Z; Rodriguez S; Impey S; Oddo J; Vitek MP; Lopez C; Christensen DJ; Sheppard B; Sears RC
    Mol Cancer Res; 2014 Jun; 12(6):924-39. PubMed ID: 24667985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.
    Janghorban M; Farrell AS; Allen-Petersen BL; Pelz C; Daniel CJ; Oddo J; Langer EM; Christensen DJ; Sears RC
    Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9157-62. PubMed ID: 24927563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer.
    González-Alonso P; Cristóbal I; Manso R; Madoz-Gúrpide J; García-Foncillas J; Rojo F
    Tumour Biol; 2015 Aug; 36(8):5753-5. PubMed ID: 26234767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential.
    Cristóbal I; Manso R; Rincón R; Caramés C; Senin C; Borrero A; Martínez-Useros J; Rodriguez M; Zazo S; Aguilera O; Madoz-Gúrpide J; Rojo F; García-Foncillas J
    Mol Cancer Ther; 2014 Apr; 13(4):938-47. PubMed ID: 24448818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.
    Khanna A; Kauko O; Böckelman C; Laine A; Schreck I; Partanen JI; Szwajda A; Bormann S; Bilgen T; Helenius M; Pokharel YR; Pimanda J; Russel MR; Haglund C; Cole KA; Klefström J; Aittokallio T; Weiss C; Ristimäki A; Visakorpi T; Westermarck J
    Cancer Res; 2013 Nov; 73(22):6757-69. PubMed ID: 24072747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor promoters--microcystin-LR, nodularin and TNF-α and human cancer development.
    Fujiki H; Suganuma M
    Anticancer Agents Med Chem; 2011 Jan; 11(1):4-18. PubMed ID: 21269254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.
    De P; Carlson J; Leyland-Jones B; Dey N
    Oncotarget; 2014 Jul; 5(13):4581-602. PubMed ID: 25015035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CIP2A inhibits PP2A in human malignancies.
    Junttila MR; Puustinen P; Niemelä M; Ahola R; Arnold H; Böttzauw T; Ala-aho R; Nielsen C; Ivaska J; Taya Y; Lu SL; Lin S; Chan EK; Wang XJ; Grènman R; Kast J; Kallunki T; Sears R; Kähäri VM; Westermarck J
    Cell; 2007 Jul; 130(1):51-62. PubMed ID: 17632056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carcinogenic aspects of protein phosphatase 1 and 2A inhibitors.
    Fujiki H; Suganuma M
    Prog Mol Subcell Biol; 2009; 46():221-54. PubMed ID: 19184590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic Cigarette Smoke Exposure Subdues PP2A Activity by Enhancing Expression of the Oncogene CIP2A.
    Nath S; Ohlmeyer M; Salathe MA; Poon J; Baumlin N; Foronjy RF; Geraghty P
    Am J Respir Cell Mol Biol; 2018 Dec; 59(6):695-705. PubMed ID: 30011381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential role for inhibition of protein phosphatase 2A tumor suppressor in salivary gland malignancies.
    Routila J; Mäkelä JA; Luukkaa H; Leivo I; Irjala H; Westermarck J; Mäkitie A; Ventelä S
    Genes Chromosomes Cancer; 2016 Jan; 55(1):69-81. PubMed ID: 26395031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A.
    Yu HC; Hung MH; Chen YL; Chu PY; Wang CY; Chao TT; Liu CY; Shiau CW; Chen KF
    Cell Death Dis; 2014 Jul; 5(7):e1359. PubMed ID: 25077545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
    Yu HC; Chen HJ; Chang YL; Liu CY; Shiau CW; Cheng AL; Chen KF
    Biochem Pharmacol; 2013 Feb; 85(3):356-66. PubMed ID: 23178652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FL118 inhibits viability and induces apoptosis of colorectal cancer cells via inactivating the CIP2A/PP2A axis.
    Lin X; Gao M; Zhang A; Tong J; Zhang X; Su Q; Yang Z; Gao H; Jiang G
    Life Sci; 2019 Dec; 239():117074. PubMed ID: 31751585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.
    Khanna A; Pimanda JE; Westermarck J
    Cancer Res; 2013 Nov; 73(22):6548-53. PubMed ID: 24204027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
    Huang Q; Qin S; Yuan X; Zhang L; Ji J; Liu X; Ma W; Zhang Y; Liu P; Sun Z; Zhang J; Liu Y
    Oncol Rep; 2017 Jul; 38(1):598-606. PubMed ID: 28560452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.